Tapdi Oksijen AS (TNZTP) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Tapdi Oksijen AS stock TRY 36.75, price TRY 21.24, upside +73.0%, quality 52 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 31, 2026.
How to read this chart
46‑month range 3.55 TRY – 32.99 TRY · fair‑value band 18.61 TRY – 47.83 TRY · the 21.24 TRY price screens below the 36.75 TRY fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 31, 2026.
Follow Tapdi Oksijen AS in your weekly email
Every Wednesday you see whether Tapdi Oksijen AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tapdi Oksijen Özel Saglik ve Egitim Hizmetleri Sanayi Ticaret A.S. provides various health services in Turkey.
Show moreShow less
It operates hospitals under the Izmir Tinaztepe University Private Buca Hospital, Tinaztepe Torbali Hospital, Tinaztepe Buca Medical Center, and Izmir Tinaztepe University Private Galen Hospital names.
The company also provides various services in areas, such as anesthesia and reanimation; biochemistry; brain and nerve surgery; cardiology, cardiology intensive care, cardiovascular surgery, cosmetic, plastic, and reconstructive surgery; dermatology; ear, nose, throat, endocrinology, eye diseases, and emergency; family medicine; gastroenterology, general intensive care, general surgery, genetic diagnosis center, and gynecology and obstetrics; and hematology.
In addition, it provides Internal medicine and interventional radiology; medical oncology and microbiology; neonatal intensive care, neurology, nuclear medicine, and nutrition and dietetics; oral and dental health, and orthopedics and traumatology; pathology, pediatric neurology, pediatric surgery, pediatrics, perinatology, physical therapy and rehabilitation, psychiatry, psychology, and pulmonary diseases; radiation oncology and radiology; and urology services.
The company was founded in 1999 and is headquartered in Izmir, Turkey.
Stock analysis
Tapdi Oksijen AS (TNZTP) currently trades at 21.24 TRY, while our model-based Fair Value estimate is 36.75 TRY, implying the stock looks roughly 42.2% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 52.40 TRY per share, and 18 of the 24 models we run sit above the 21.24 TRY price.
Bear case: the Asset-Based group reads lowest at 13.40 TRY, and 6 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: 18.61 TRY (bear) to 47.83 TRY (bull), the price of 21.24 TRY sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Tapdi Oksijen AS reported revenue of 3.4B TRY in FY2025 versus 310M TRY in FY2021, a compound +82.4%/yr. Reported net income was 696M TRY in FY2025, compounding +80.3%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 8.5B TRY (≈ $170M) Micro · P/E ratio 15.6 · P/S ratio 3.17 · EPS (TTM) 1.36 TRY · Net margin 20.3% · Return on equity 4.6% · Return on assets (EBIT) 5.2% · Operating margin 23.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 73%, TNZTP screens cheaper than that median.
Fair Value models
Bear18.61 TRYFair Value 36.75 TRYBull47.83 TRY
Price 21.24 TRY · Upside +73.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.14 TRY per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.86/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+19.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+76.2%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TRY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TRY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+60.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+60.2%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 28%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+28.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Turkey: IMF forecast 19.3% a year to 2030, 28.5% from 2016 to 2025) that is about +8.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 241 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside+73.0% · Top 25%
Profitability
Return on equity (12 months)4.6% · Below median
Return on assets7.3% · Above median
Net margin (12 months)10.8% · Above median
Operating margin (12 months)23.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)1.5% · Below median
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Tapdi Oksijen AS Fair Value". https://www.fairvalue-calculator.com/stock/TNZTP
Frequently asked questions
Is Tapdi Oksijen AS (TNZTP) overvalued or undervalued?
As of Oct 31, 2026, our model estimates a fair value of 36.75 TRY versus a price of 21.24 TRY, about +73% upside (undervalued).
What is the fair value of TNZTP?
Our model-based fair value for Tapdi Oksijen AS is 36.75 TRY (as of Oct 31, 2026), built from audited fundamentals. The current price: 21.24 TRY.
What is the quality score of TNZTP?
Tapdi Oksijen AS has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tapdi Oksijen AS (TNZTP)?
Our model-based price target is the fair value of 36.75 TRY (as of Oct 31, 2026) from 24 valuation models. Cautious scenario 18.61 TRY, optimistic scenario 47.83 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the Tapdi Oksijen AS stock forecast for 2026?
Our models put fair value at 36.75 TRY, about +73% upside versus a price of 21.24 TRY (undervalued). Cautious scenario 18.61 TRY, optimistic scenario 47.83 TRY. The calculation is refreshed regularly with new filings.
What is the revenue of Tapdi Oksijen AS (TNZTP)?
Tapdi Oksijen AS reported trailing-twelve-month revenue of about 3.5B TRY (latest available figure, as of Oct 31, 2026).
What growth is priced into Tapdi Oksijen AS (TNZTP)?
For today's price to be fair in a discounted-cash-flow model, Tapdi Oksijen AS would have to grow free cash flow by +28.9 % per year for five years (discount rate 15.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +76.2 % per year. As of Oct 31, 2026.
What discount rate (WACC) does the fair value of TNZTP use?
Our models discount Tapdi Oksijen AS at 15.7 %: a base by market capitalisation (micro), damped by beta 0.12, country premium for Turkey. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tapdi Oksijen AS that is +28.9 % per year a year over ten years, using the same discount rate (15.7 %) and the same formula as our fair value.
How much growth has Tapdi Oksijen AS (TNZTP) delivered so far?
Over the past 5 years revenue at Tapdi Oksijen AS grew +76.2 % a year. The price currently implies +28.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Tapdi Oksijen AS (TNZTP) growing?
The median revenue growth in the sector is +13.2 % a year. That is the yardstick for the growth priced into Tapdi Oksijen AS (+28.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Tapdi Oksijen AS (TNZTP)?
The free-cash-flow yield on the price is 3.53 %: that much free cash flow Tapdi Oksijen AS produces per unit of market value. When it exceeds the discount rate of our models (15.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Tapdi Oksijen AS (TNZTP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tapdi Oksijen AS it is 36.75 TRY per share (as of Oct 31, 2026), against a price of 21.24 TRY. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Tapdi Oksijen AS stock overvalued or undervalued in 2026?
As of Oct 31, 2026, TNZTP trades below its calculated fair value: price 21.24 TRY, fair value 36.75 TRY, a gap of about +73% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TNZTP?
No. The price is what the market pays today (21.24 TRY); the fair value is what the company's own numbers justify (36.75 TRY). For Tapdi Oksijen AS the two are 15.51 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is Tapdi Oksijen AS worth?
The market values Tapdi Oksijen AS at about 8.5B TRY (market capitalisation, as of Oct 31, 2026). Per share that is 21.24 TRY; our models calculate a fair value of 36.75 TRY per share.
What do the bullish and bearish scenarios say about TNZTP?
Our models span a range for Tapdi Oksijen AS: cautious scenario 18.61 TRY, base 36.75 TRY, optimistic 47.83 TRY per share (as of Oct 31, 2026, price 21.24 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TNZTP?
Tapdi Oksijen AS trades at a price-to-earnings ratio of 15.6 (as of Oct 31, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 36.75 TRY is built from several models across several years. Other multiples: P/B 1.1, P/S 2.4, EV/EBITDA 6.5.
How solid is the balance sheet of Tapdi Oksijen AS (TNZTP)?
Balance-sheet figures for Tapdi Oksijen AS (as of Oct 31, 2026): return on equity 4.6%, debt of 0.01 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is TNZTP from its 52-week high?
Tapdi Oksijen AS trades at 21.24 TRY, about 34% below its 52-week high of 32.00 TRY and 5% above the low of 20.26 TRY (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of 36.75 TRY is for.
Which stocks are comparable to Tapdi Oksijen AS?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tapdi Oksijen AS stock attractive at the current price?
The data as of Oct 31, 2026: price 21.24 TRY, calculated fair value 36.75 TRY (+73%), Quality Score 52/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TNZTP calculated?
We run Tapdi Oksijen AS through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 36.75 TRY, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.5 % above its aggregate fair value. Tapdi Oksijen AS currently trades 42 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tapdi Oksijen AS (TNZTP)?
The closing price on Oct 30, 2026 was 21.24 TRY. Our model-based fair value is 36.75 TRY, about +73% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tapdi Oksijen AS right now?
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (18.61 TRY to 47.83 TRY) leaves room in how you read the outcome.
Key figures of Tapdi Oksijen AS
How large is the market capitalisation of Tapdi Oksijen AS (TNZTP)?
The market capitalisation of Tapdi Oksijen AS is 8.5B TRY (≈ $170M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tapdi Oksijen AS (TNZTP)?
The price-to-sales ratio of Tapdi Oksijen AS is 3.17 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tapdi Oksijen AS (TNZTP)?
Earnings per share at Tapdi Oksijen AS are 1.36 TRY (price ÷ EPS = P/E 15.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Tapdi Oksijen AS (TNZTP)?
The net margin of Tapdi Oksijen AS is 20.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tapdi Oksijen AS (TNZTP)?
The return on equity (ROE) of Tapdi Oksijen AS is 4.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tapdi Oksijen AS (TNZTP)?
On an EBIT basis the return on assets of Tapdi Oksijen AS is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tapdi Oksijen AS (TNZTP)?
The operating margin of Tapdi Oksijen AS is 23.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tapdi Oksijen AS (TNZTP)?
Revenue at Tapdi Oksijen AS is growing +1.5% versus a year earlier (3y avg +47.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tapdi Oksijen AS (TNZTP)?
Earnings per share at Tapdi Oksijen AS are growing −92.9% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Tapdi Oksijen AS in the live analysis
One click puts Tapdi Oksijen AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 31, 2026